Catalent Launches New Business Unit

Catalent has launched a new business unit to bring new pharmaceutical and biologic products to the market.

Reportedly, the new segment will build upon Catalent’s substantial expertise and experience in supporting the development and testing of drugs and biologics through scientific, regulatory and clinical trial supply chain services.

The company has also reported the appointment of Scott Houlton as group president for the new segment, effective August 31st.

John Chiminski, president and CEO of Catalent, said: “I expect the Development and Clinical Services segment to bring even more value to our customers through a sharpened focus and an integrated approach to solving the challenges our R&D customers face, and believe that this will result in significant new growth for the segment. As we have been involved in more than a third of NDAs and BLAs approved by the FDA in the last seven years, we know what it takes to bring a customer’s drug or biologic to market – each step of the way.

“I am also very pleased to welcome Scott to Catalent to lead this segment. He is experienced at driving growth, passionate about serving customers, and committed to operational excellence. I expect great things from Scott and the nearly 900 employees of this new segment,” he added.